TWILITAKA

Members of the Exchange are hereby notified that in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Securities Contract (Regulations) Rules, 1957 and Bye Laws & Regulations of National Stock Exchange of India Limited, it has been decided to delist (withdraw the admission to dealings in) equity shares of the Twilight Litaka Pharma Limited w.e.f. July 02, 2018.

Members of the Exchange are hereby informed that the Exchange on February 02, 2018 has issued public notice in the newspaper for proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

ACG Pampac Machines Pvt Ltd has submitted to the Exchange vide letter dated July 28, 2016 a copy of disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

ACG Pam Pac Machines Pvt Ltd has submitted to the Exchange vide letter dated July 28, 2016 a copy of disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Members of the Exchange are hereby informed that trading in the equity shares of Twilight Litaka Pharma Limited will be suspended w.e.f. January 02, 2015 (i.e. closing hours of trading on January 01, 2015) pursuant to order dated April 30, 2014 passed by the Hon'ble High Court, Bombay, in Company Petition No.471 of 2012, the Official Liquidator attached to the said Court has been appointed as the Provisional Liquidator of M/s Twilight Litaka Pharma Limited (In Liqn.).

Twilight Litaka Pharma Limited has submitted to the Exchange a copy of outcome of the Annual General Meeting of the Company held on November 29, 2014.

Twilight Litaka Pharma Limited has informed the Exchange that the Company has fixed Book Closure from November 26, 2014 to November 29, 2014 for the purpose of Annual General Meeting (AGM) scheduled to be held on November 29, 2014.

Twilight Litaka Pharma Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2014.

Twilight Litaka Pharma Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2014.

Twilight Litaka Pharma Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

Twilight Litaka Pharma Limited has submitted to the exchange the standalone financial results for the period ended 31-dec-2013.

Twilight Litaka Pharma Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company to be held on December 30, 2013.

Twilight Litaka Pharma Limited has informed the Exchange that Mr. Abhijit bora, Executive Director, Mr. Nikhil Kulkarni, Company Secretary and Mr. Prashant Shimpi, Manager Legal have left the Company and therefore they are not members of the management.

Twilight Litaka Pharma Limited has informed the Exchange that the Company has fixed Book Closure from December 27, 2013 to December 30, 2013 for the purpose of Annual General Meeting to be held on December 30, 2013.

Twilight Litaka Pharma Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2013.

Twilight Litaka Pharma Limited has informed the Exchange, vide letter dated July 10, 2013 regarding the Result of Postal Ballot.

Twilight Litaka Pharma Limited has submitted to the Exchange a copy of Notice of Postal Ballot pursuant to Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2011.

Twilight Litaka Pharma Limited has informed the Exchange regarding outcome of Board of Directors meeting held on May 15, 2013.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2013.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.

Twilight Litaka Pharma Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the Company held on December 31, 2012.

Twilight Litaka Pharma Limited has informed the Exchange that the Board of Directors in its meeting held on December 03, 2012 has decided to hold ensuing Annual General Meeting on December 31, 2012. The Register of Members and Share Transfer Books will remain closed from December 26, 2012 to December 31, 2012 (both days inclusive) for the purpose of Annual General Meeting.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012.

Twilight Litaka Pharma Limited has informed the Exchange regarding the Outcome of Extra Ordinary General Meeting of the Company held on September 29, 2012.

Twilight Litaka Pharma Limited has informed the Exchange that the Registrar of Companies, Maharashtra, Pune has accorded their approval for holding of Annual General Meeting within extended time of three months i.e. on or before December 31, 2012.

Twilight Litaka Pharma Limited has submitted to the Exchange a copy of Notice of Extraordinary General Meeting to be held on September 29, 2012.

Twilight Litaka Pharma Limited has informed the Exchange regarding the Outcome of the Meeting of the Board of Directors of the Company held on September 01, 2012.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Twilight Litaka Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 12, 2012, inter alia, has considered and approved shifting of the registered Office of the Company within local limits of Pune city from 16-A, Himalaya Estate, Shivajinagar, Pune - 411 005, Maharashtra, India to B-22, 'H' Block, M.I.D.C. Pimpri, Pune - 411 018 Maharashtra, India with immediate effect.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended December 31,2011.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Twilight Litaka Pharma Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the Company held on September 29, 2011.

Twilight Litaka Pharma Limited has informed the Exchange that the Annual General Meeting of the Company will be held on September 29, 2011. The Register of Members and the Share Transfer Books of the Company will remain closed from September 26, 2011 to September 29, 2011 (both days inclusive) for the purpose of the Annual General Meeting of the Company and Dividend.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Twilight Litaka Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 27, 2011 has recommended dividend @ 30% i.e. Rs.1.50 Per share for 2010-11 on the Paid up Equity Share Capital of the Company (Rs.12,39,06,425/- comprising of 2,47,81,285 Equity Shares of Rs.5/- each fully paid up).

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Twilight Litaka Pharma Limited has submitted the Exchange a copy of Disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Twilight Litaka Pharma Limited has submitted the Exchange a copy of Disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Twilight Litaka Pharma Limited has submitted the Exchange a copy of Disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Twilight Litaka Pharma Limited has informed the Exchange that the Allotment Committee of the Board of Directors, allotted 35,00,000 Equity Shares of Rs.5/- each at a premium of Rs.81/- per equity Share on conversion of 35,00,000 Convertible Warrants issued by the Company on March 13, 2010 in pursuance of special resolution passed in the Extra Ordinary General Meeting held on March 2, 2010. The issued and paid up capital has thus gone up from Rs.10,64,06,425/- to Rs. 12,39,06,425 /- i.e. 2,47,81,285 Equity Shares of Rs.5/- each w. e. f. June 16, 2011.

Twilight Litaka Pharma Limited has submitted to the Exchange a copy of intimation pursuant to Clause 31 of the Listing Agreement.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Twilight Litaka Pharma Limited has informed the Exchange that w.e.f. April 11, 2011, Mr. Nikhil Kulkarni appointed as Assistant Company Secretary, will be appointed as Compliance Officer in place of Mr. S. D. Tole.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Twilight Litaka Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Twilight Litaka Pharma Limited has informed the Exchange that Twilight Litaka Pharma Ltd. (Twilight) has entered into an agreement on October 13, 2010, with M/s. Interpro Healthcare Ltd., (Interpro) a company based in South Africa in connection with supply of technical know-how and for its products with the said company. As per the said arrangement Twilight will provide technical know-how to Interpro against which said Company will allot fully paid 26% equity shares in the share capital of Interpro. Under this arrangement Interpro will be required to purchase the products exclusively from Twil

Twilight Litaka Pharma Limited has informed the Exchange that "Our Director Prof. P.D. Gupte, who was liable to retire by rotation in the Annual General Meeting, held on 25.09.2010, and informed to the Company that he is not willing to be re-appointed due to his old age. Accordingly his directorship is ceased on 25.09.2010".